| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439354 | European Journal of Cancer | 2018 | 11 Pages |
Abstract
Standard treatment is feasible with good outcomes in a large proportion of elderly DLBCL-patients. Planned dose reduction in patients aged â¥80 years had no negative impact on OS.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maja Bech Juul, Pernille Hammershoej Jensen, Henriette Engberg, Sonja Wehberg, Andriette Dessau-Arp, Donika Haziri, Helene Bjoerg Kristensen, Joachim Baech, Lene Schurmann, Michael Roost Clausen, Rebecca Valentin, Lene Meldgaard Knudsen, Lars Munksgaard,